BG106594A - Pteridinones as kinase inhibitors - Google Patents
Pteridinones as kinase inhibitorsInfo
- Publication number
- BG106594A BG106594A BG106594A BG10659402A BG106594A BG 106594 A BG106594 A BG 106594A BG 106594 A BG106594 A BG 106594A BG 10659402 A BG10659402 A BG 10659402A BG 106594 A BG106594 A BG 106594A
- Authority
- BG
- Bulgaria
- Prior art keywords
- substituted
- compounds
- lower alkyl
- hydrogen
- members
- Prior art date
Links
- VWXIHLCLIOQWRA-UHFFFAOYSA-N 1h-pteridin-2-one Chemical class N1=CC=NC2=NC(O)=NC=C21 VWXIHLCLIOQWRA-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 108091007914 CDKs Proteins 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15409599P | 1999-09-15 | 1999-09-15 | |
| PCT/US2000/017037 WO2001019825A1 (fr) | 1999-09-15 | 2000-06-21 | Pteridinones utilisees comme inhibiteurs de kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG106594A true BG106594A (en) | 2002-12-29 |
Family
ID=22549985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG106594A BG106594A (en) | 1999-09-15 | 2002-04-10 | Pteridinones as kinase inhibitors |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7169778B2 (fr) |
| EP (1) | EP1409487A1 (fr) |
| JP (1) | JP2003509425A (fr) |
| KR (1) | KR20020027649A (fr) |
| CN (1) | CN1373763A (fr) |
| AP (1) | AP2002002479A0 (fr) |
| AU (1) | AU777468B2 (fr) |
| BG (1) | BG106594A (fr) |
| BR (1) | BR0013952A (fr) |
| CA (1) | CA2393896A1 (fr) |
| CR (1) | CR6586A (fr) |
| CZ (1) | CZ2002846A3 (fr) |
| DZ (1) | DZ3186A1 (fr) |
| EA (1) | EA005287B1 (fr) |
| EE (1) | EE200200140A (fr) |
| HK (1) | HK1048992A1 (fr) |
| HU (1) | HUP0202713A3 (fr) |
| IL (1) | IL148614A0 (fr) |
| IS (1) | IS6298A (fr) |
| MA (1) | MA26819A1 (fr) |
| MX (1) | MXPA02001108A (fr) |
| NO (1) | NO20021239L (fr) |
| NZ (1) | NZ516872A (fr) |
| OA (1) | OA12010A (fr) |
| PL (1) | PL353269A1 (fr) |
| SK (1) | SK3542002A3 (fr) |
| WO (1) | WO2001019825A1 (fr) |
| YU (1) | YU18502A (fr) |
| ZA (1) | ZA200200896B (fr) |
Families Citing this family (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276506B2 (en) | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359551A (en) * | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| US6858608B2 (en) * | 2001-01-09 | 2005-02-22 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
| US6887873B2 (en) | 2001-03-23 | 2005-05-03 | Aventis Pharma S.A. | Triazine derivatives and their application as antitelomerase agents |
| WO2002076985A1 (fr) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| DE60212836T2 (de) * | 2001-05-16 | 2007-01-25 | Gpc Biotech Ag | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
| AU2002316421B2 (en) * | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
| SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| UY27427A1 (es) * | 2001-09-04 | 2003-03-31 | Boehringer Ingelheim Pharma | Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos |
| US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| EP1453516A2 (fr) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament |
| JP4460292B2 (ja) * | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
| NZ534069A (en) | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| DE10212100A1 (de) * | 2002-03-11 | 2003-10-23 | Schering Ag | CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| AU2003250701A1 (en) * | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| US7067658B2 (en) * | 2002-09-30 | 2006-06-27 | Bristol-Myers Squibb Company | Pyridino and pyrimidino pyrazinones |
| RU2351586C2 (ru) * | 2002-10-03 | 2009-04-10 | Таргеджен, Инк. | Васкулостатические агенты и способы их применения |
| CA2542007C (fr) * | 2002-10-09 | 2010-06-29 | Wayne R. Danter | Inhibiteurs de proteine tyrosine kinase |
| WO2004048343A1 (fr) * | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Pyrimidines inhibitrices de chk-, pdk- et de akt, production et utilisation de ces composes comme agents pharmaceutiques |
| EP1590341B1 (fr) * | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | Heterocycles 2-aminopyridines substitues utilises comme inhibiteurs de la proliferation cellulaire |
| US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE50307267D1 (de) * | 2003-02-26 | 2007-06-21 | Boehringer Ingelheim Pharma | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| GB0328243D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| US7405220B2 (en) | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006002367A1 (fr) * | 2004-06-23 | 2006-01-05 | Irm Llc | Composes et compositions utilises en tant qu'inhibiteurs des proteines kinases |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US7423051B2 (en) | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 2,6-diaminopyridine derivatives |
| US7423053B2 (en) | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 4-Aminothiazole derivatives |
| DE102004034623A1 (de) * | 2004-07-16 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| EP1630163A1 (fr) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments |
| EP1632493A1 (fr) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dérivés de dihydropteridine, méthodes de préparation et utilisation en tant que médicament |
| CA2575804A1 (fr) * | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinones utilisees en tant qu'inhibiteurs des plk (polo-like-kinases) |
| WO2006021548A1 (fr) * | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, leur procede de production, et leur utilisation en tant que medicaments |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| US7767687B2 (en) * | 2004-12-13 | 2010-08-03 | Biogen Idec Ma Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| ATE479434T1 (de) | 2006-02-14 | 2010-09-15 | Vertex Pharma | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine |
| EP2010542B1 (fr) * | 2006-04-12 | 2012-01-25 | Vertex Pharmaceuticals Incorporated | 4,5-dihydro-[1,2,4]triazolo[4,3-f]ptéridines en tant que inhibiteurs de la kinase de protein plk1 pour le traitement de desordres proliferatives |
| CN101448830A (zh) * | 2006-05-19 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 作为抗增殖剂的二氢碟啶化合物 |
| WO2008009909A1 (fr) * | 2006-07-17 | 2008-01-24 | Astrazeneca Ab | Ptéridimones en tant que modulateurs de la kinase de type polo |
| WO2008009078A2 (fr) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales |
| WO2008009079A2 (fr) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Ptéridines substituées utilisables pour le traitement et la prévention des infections virales |
| WO2008040951A1 (fr) * | 2006-10-03 | 2008-04-10 | Astrazeneca Ab | Composés |
| US7893066B2 (en) | 2006-10-05 | 2011-02-22 | Gilead Palo Alto, Inc. | Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors |
| RU2009112397A (ru) | 2006-10-05 | 2010-10-10 | Си Ви ТЕРАПЬЮТИКС, ИНК (US) | Бициклические азотсодержащие гетероциклические соединения для применения в качестве ингибиторов стеароил соа десатуразы |
| WO2008083491A1 (fr) | 2007-01-11 | 2008-07-17 | Critical Outcome Technologies Inc. | Composés et méthode de traitement un cancer |
| EP1953163A1 (fr) | 2007-02-01 | 2008-08-06 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dérivés de Pteridinone comme inhibiteurs des Kinases PI3 |
| US7662819B2 (en) | 2007-04-09 | 2010-02-16 | Gilead Palo Alto, Inc. | Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors |
| EP2185559A1 (fr) * | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Forme cristalline d'un dérivé de dihydroptéridione |
| BRPI0817315A2 (pt) | 2007-09-25 | 2015-03-17 | Takeda Pharmaceutical | Inibidores de quinase do tipo polo |
| EP2215091B1 (fr) | 2007-12-04 | 2016-03-30 | Nerviano Medical Sciences S.r.l. | Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase |
| US8466151B2 (en) * | 2007-12-26 | 2013-06-18 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| JP2011516498A (ja) | 2008-04-04 | 2011-05-26 | ギリアード サイエンシーズ, インコーポレイテッド | ステアロイル−CoAデサチュラーゼの阻害剤として使用するためのトリアゾロピリジノン誘導体 |
| EP3023426A1 (fr) | 2008-07-17 | 2016-05-25 | Critical Outcome Technologies, Inc. | Composés inhibiteurs à base de thiosemicarbazone et procédés de traitement du cancer |
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| WO2011031965A1 (fr) | 2009-09-14 | 2011-03-17 | Gilead Sciences, Inc. | Modulateurs des récepteurs de type toll (tlr) |
| CN102020643A (zh) | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| SG179207A1 (en) | 2009-09-25 | 2012-04-27 | Vertex Pharma | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| MX2012003484A (es) | 2009-09-25 | 2012-04-20 | Vertex Pharma | Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa. |
| WO2011050245A1 (fr) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Hétéroaryles bicycliques formant inhibiteurs de la kinase |
| US20120329803A1 (en) | 2010-02-17 | 2012-12-27 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for production and use thereof |
| WO2011120153A1 (fr) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Composés et méthodes pour le traitement du vih |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| US8546566B2 (en) * | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| US9351974B2 (en) | 2011-11-10 | 2016-05-31 | OSI Pharmaceuticals, LLC | Substituted pteridinones for the treatment of cancer |
| CN106008511B (zh) * | 2012-05-14 | 2018-08-14 | 华东理工大学 | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 |
| GB201209613D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| JP2016525532A (ja) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄異形成症候群の処置 |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| BR112016022056B1 (pt) | 2014-03-26 | 2023-04-11 | Astex Therapeutics Limited | Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico |
| US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| WO2015193228A1 (fr) * | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | 1,4-dihydropyrido[3,4-b]pyrazinones inhibitrices de protéine bet, à groupe éther ou amino aromatique para-substitué |
| SI3166607T1 (sl) | 2014-07-11 | 2023-01-31 | Gilead Sciences, Inc. | Modulatorji toličnih receptorjev za zdravljenje HIV-a |
| CN107074860B (zh) | 2014-09-16 | 2022-07-15 | 吉利德科学公司 | 制备toll样受体调节剂的方法 |
| CN110305133A (zh) | 2014-09-16 | 2019-10-08 | 吉利德科学公司 | Toll样受体调节剂的固体形式 |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| SG11201606876RA (en) | 2015-03-04 | 2016-10-28 | Gilead Sciences Inc | Toll like receptor modulator compounds |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CN106279173A (zh) * | 2015-05-29 | 2017-01-04 | 华东理工大学 | 蝶啶酮衍生物作为egfr抑制剂的应用 |
| WO2017050865A1 (fr) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | Bi-hétéroaryle 1,4-benzodiazépines substituées et leurs utilisations pour le traitement du cancer |
| HUE050567T2 (hu) | 2015-09-23 | 2020-12-28 | Janssen Pharmaceutica Nv | Triciklusos heterociklusok rák kezelésére |
| CN106892922B (zh) * | 2015-12-18 | 2019-04-19 | 华东理工大学 | 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用 |
| CN107151249B (zh) * | 2016-03-04 | 2020-08-14 | 华东理工大学 | 作为flt3抑制剂的蝶啶酮衍生物及应用 |
| SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
| WO2018045150A1 (fr) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Dérivés de 4,6-diamino-pyrido [3,2-d] pyrimidine en tant que modulateurs du récepteur de type toll |
| CN108721298A (zh) * | 2017-04-19 | 2018-11-02 | 华东理工大学 | 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用 |
| WO2020033823A1 (fr) * | 2018-08-10 | 2020-02-13 | Yale University | Inhibiteurs de pi5p4k alpha/bêta à petites molécules et procédés de traitement les utilisant |
| TWI831829B (zh) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| CN111217815B (zh) * | 2018-11-27 | 2021-06-18 | 沈阳药科大学 | 含有喋啶酮骨架的化合物及其制备方法和应用 |
| WO2020142612A1 (fr) * | 2019-01-03 | 2020-07-09 | Genentech, Inc. | Composés de pyrido-pyrimidinone et de ptéridinone utilisés en tant qu'inhibiteurs de l'enzyme nécessitant l'inositol i (ire i alpha) à activité endoribonucléase pour le traitement de maladies cancéreuses |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| CN110357885A (zh) * | 2019-07-24 | 2019-10-22 | 江南大学 | 一种蝶啶类化合物及其在药学上的应用 |
| CN113801118A (zh) * | 2020-06-12 | 2021-12-17 | 华东理工大学 | 作为rsk抑制剂的蝶啶酮衍生物及其应用 |
| WO2022177302A1 (fr) * | 2021-02-17 | 2022-08-25 | 보령제약 주식회사 | Composé cyclique fusionné à la pyrimidine avec une activité d'inhibition de l'adn-pk et son utilisation |
| CN113087708A (zh) * | 2021-04-06 | 2021-07-09 | 南方医科大学 | 一种蝶啶酮类化合物及其应用 |
| CN115850281A (zh) * | 2021-09-24 | 2023-03-28 | 华东理工大学 | 蝶啶酮衍生物及其应用 |
| CN115010711B (zh) * | 2022-07-12 | 2024-12-03 | 江南大学 | 一种蝶啶7(8h)-酮类化合物及其在药学上的应用 |
| CN118047779B (zh) * | 2022-11-09 | 2025-02-11 | 沈阳药科大学 | 含苯联杂芳基的二氢喋啶酮衍生物及其用途 |
| WO2024199388A1 (fr) * | 2023-03-29 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | Composé agissant comme inhibiteur de myt1 |
| WO2026024674A1 (fr) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Méthodes de traitement de cancers associés à skp2 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53124296A (en) * | 1977-04-05 | 1978-10-30 | Mitsubishi Chem Ind Ltd | Penicillin derivatives |
| CA2223081C (fr) | 1995-06-07 | 2001-03-06 | Pfizer Inc. | Derives de pyrimidine heterocycliques a noyaux condenses |
| US6395733B1 (en) * | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
| EP0837063A1 (fr) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | Dérivés de 4-aminoquinazoline |
| JPH1180131A (ja) * | 1997-09-01 | 1999-03-26 | Mitsubishi Chem Corp | エチニルピリミジン誘導体 |
| WO2002076985A1 (fr) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives |
-
2000
- 2000-06-21 JP JP2001523402A patent/JP2003509425A/ja not_active Abandoned
- 2000-06-21 AP APAP/P/2002/002479A patent/AP2002002479A0/en unknown
- 2000-06-21 WO PCT/US2000/017037 patent/WO2001019825A1/fr not_active Ceased
- 2000-06-21 CZ CZ2002846A patent/CZ2002846A3/cs unknown
- 2000-06-21 KR KR1020027003387A patent/KR20020027649A/ko not_active Withdrawn
- 2000-06-21 CN CN00812620A patent/CN1373763A/zh active Pending
- 2000-06-21 MX MXPA02001108A patent/MXPA02001108A/es active IP Right Grant
- 2000-06-21 CA CA002393896A patent/CA2393896A1/fr not_active Abandoned
- 2000-06-21 YU YU18502A patent/YU18502A/sh unknown
- 2000-06-21 HK HK03101140.4A patent/HK1048992A1/zh unknown
- 2000-06-21 EA EA200200078A patent/EA005287B1/ru not_active IP Right Cessation
- 2000-06-21 US US10/070,530 patent/US7169778B2/en not_active Expired - Fee Related
- 2000-06-21 DZ DZ003186A patent/DZ3186A1/fr active
- 2000-06-21 EE EEP200200140A patent/EE200200140A/xx unknown
- 2000-06-21 OA OA1200200058A patent/OA12010A/en unknown
- 2000-06-21 SK SK354-2002A patent/SK3542002A3/sk not_active Application Discontinuation
- 2000-06-21 BR BR0013952-1A patent/BR0013952A/pt not_active Application Discontinuation
- 2000-06-21 NZ NZ516872A patent/NZ516872A/en unknown
- 2000-06-21 HU HU0202713A patent/HUP0202713A3/hu unknown
- 2000-06-21 PL PL00353269A patent/PL353269A1/xx not_active Application Discontinuation
- 2000-06-21 AU AU56295/00A patent/AU777468B2/en not_active Ceased
- 2000-06-21 EP EP00941604A patent/EP1409487A1/fr not_active Withdrawn
- 2000-06-21 IL IL14861400A patent/IL148614A0/xx unknown
-
2002
- 2002-01-31 ZA ZA200200896A patent/ZA200200896B/en unknown
- 2002-02-11 CR CR6586A patent/CR6586A/es not_active Application Discontinuation
- 2002-03-12 MA MA26550A patent/MA26819A1/fr unknown
- 2002-03-13 IS IS6298A patent/IS6298A/is unknown
- 2002-03-13 NO NO20021239A patent/NO20021239L/no not_active Application Discontinuation
- 2002-04-10 BG BG106594A patent/BG106594A/xx unknown
-
2006
- 2006-10-27 US US11/553,935 patent/US20070049600A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DZ3186A1 (fr) | 2001-03-22 |
| HUP0202713A2 (hu) | 2002-12-28 |
| HUP0202713A3 (en) | 2005-02-28 |
| US20070049600A1 (en) | 2007-03-01 |
| EP1409487A1 (fr) | 2004-04-21 |
| MA26819A1 (fr) | 2004-12-20 |
| NO20021239D0 (no) | 2002-03-13 |
| EE200200140A (et) | 2003-04-15 |
| IL148614A0 (en) | 2002-09-12 |
| EA200200078A1 (ru) | 2002-12-26 |
| KR20020027649A (ko) | 2002-04-13 |
| IS6298A (is) | 2002-03-13 |
| WO2001019825A1 (fr) | 2001-03-22 |
| YU18502A (sh) | 2004-12-31 |
| CA2393896A1 (fr) | 2001-03-22 |
| AP2002002479A0 (en) | 2002-06-30 |
| SK3542002A3 (en) | 2003-04-01 |
| NO20021239L (no) | 2002-03-13 |
| PL353269A1 (en) | 2003-11-03 |
| NZ516872A (en) | 2003-10-31 |
| EA005287B1 (ru) | 2004-12-30 |
| BR0013952A (pt) | 2002-05-14 |
| AU777468B2 (en) | 2004-10-21 |
| US20030130286A1 (en) | 2003-07-10 |
| CR6586A (es) | 2004-02-02 |
| OA12010A (en) | 2006-04-19 |
| MXPA02001108A (es) | 2002-08-20 |
| HK1048992A1 (zh) | 2003-04-25 |
| US7169778B2 (en) | 2007-01-30 |
| AU5629500A (en) | 2001-04-17 |
| JP2003509425A (ja) | 2003-03-11 |
| ZA200200896B (en) | 2003-07-30 |
| CZ2002846A3 (cs) | 2003-02-12 |
| CN1373763A (zh) | 2002-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2002002479A0 (en) | Pteridinones as kinase inhibitors. | |
| YU73300A (sh) | Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije | |
| YU50402A (sh) | Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze | |
| MXPA02011426A (es) | Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa. | |
| WO2003024967A3 (fr) | Composes chimiques | |
| DE60128343D1 (de) | Pyrimidine verbindungen | |
| TNSN07281A1 (en) | Pyrazole derivatives for the inhibition of cdk's and gsk's | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| PL1635835T3 (pl) | Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF | |
| NZ503828A (en) | Aminothiazole inhibitors of cyclin dependent kinases | |
| GEP20063915B (en) | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS | |
| EP1620108A4 (fr) | Composes de pyrazole-amines utiles en tant qu'inhibiteurs de kinases | |
| UA72930C2 (uk) | Похідні n-гетероциклічних сполук як інгібітори синтази оксиду азоту (nos) | |
| GR3006247T3 (fr) | ||
| MXPA05009151A (es) | Inhibidores de cinasa heterociclica. | |
| AR045006A1 (es) | Derivados de quinazolinona 5-sustituidos | |
| IL153748A0 (en) | Processes for preparing azacycloalkanoylaminothiazole derivatives | |
| YU18404A (sh) | Hemijska jedinjenja | |
| DK0888356T3 (da) | Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere | |
| DE60144246D1 (de) | Imidazolderivate, verfahren zu deren herstellung und deren verwendung | |
| AR027035A1 (es) | Pirroles sustituidos | |
| HRP20050617A2 (en) | Imidazol derivatives having affinity for alpha 2 receptors activity | |
| EA200200379A3 (ru) | Новые соединения пиримидин-4-она, способ их получения и содержащие их фармацевтические композиции | |
| UA90461C2 (en) | Pyrazole derivatives as protein kinase modulators | |
| PE20030154A1 (es) | Eurotinona y derivados de la misma, procedimiento para su preparacion |